サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1386335

B細胞リンパ腫治療市場レポート：2030年までの動向、予測、競合分析

B-Cell Lymphoma Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

B細胞リンパ腫治療市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年10月03日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

B細胞リンパ腫治療の動向と予測

世界のB細胞リンパ腫治療市場は、2024年から2030年までのCAGRが7.8％で、2030年までに推定102億8,000万米ドルに達すると予測されます。この市場の主な促進要因は、B細胞リンパ腫の罹患率の増加と治療選択肢の継続的な進歩です。世界のB細胞リンパ腫治療市場の将来は、病院、専門クリニック、在宅ヘルスケア市場でのビジネスチャンスにより有望視されています。

B細胞リンパ腫治療市場の洞察

びまん性大細胞型B細胞リンパ腫は、症例数の増加とB細胞リンパ腫の有病率の増加により、予測期間中も最大セグメントであり続けるとLucintelは予測しています。

この市場において、病院は幅広いB細胞リンパ腫治療を実施するために必要な設備と専門知識を提供するため、最大セグメントであり続けると思われます。

北米は、最新のB細胞リンパ腫治療を受けられるヘルスケアシステムが発達しているため、予測期間中も最大セグメントであり続けると思われます。

市場規模・推計：B細胞リンパ腫治療の市場規模を金額（Bドル）で推計。

動向と予測分析：各種セグメント・地域別の市場動向（2018年～2023年）と予測（2024年～2030年）。

セグメント別分析：B細胞リンパ腫治療薬市場規模をタイプ別、エンドユース別、流通チャネル別、地域別に金額（億米ドル）で推計。

地域別分析：B細胞リンパ腫治療薬市場の北米、欧州、アジア太平洋地域、その他世界のその他の地域内訳。

成長機会：B細胞リンパ腫治療市場のタイプ、エンドユース、流通チャネル、地域別の成長機会を分析。

戦略分析：B細胞リンパ腫治療市場のM&A、新製品開発、競合情勢など。

ポーターのファイブフォースモデルに基づく業界の競合強度分析。

本レポートは以下の11の主要な質問に回答しています：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のB細胞リンパ腫治療市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018年～2023年）と予測（2024年～2030年）
  • 世界のB細胞リンパ腫治療市場動向（2018年～2023年）と予測（2024年～2030年）
  • 種類別の世界のB細胞リンパ腫治療市場
    • びまん性大細胞型B細胞リンパ腫
    • リンパ形質細胞性リンパ腫
    • 有毛細胞白血病
    • 原発性中枢神経系リンパ腫
    • 原発性眼内リンパ腫
    • その他
  • 最終用途別の世界のB細胞リンパ腫治療市場
    • 病院
    • 専門クリニック
    • 在宅ヘルスケア
    • その他
  • 流通チャネル別の世界のB細胞リンパ腫治療市場
    • 直接入札
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界のB細胞リンパ腫治療市場
  • 北米のB細胞リンパ腫治療市場
  • 欧州のB細胞リンパ腫治療市場
  • アジア太平洋のB細胞リンパ腫治療市場
  • その他の地域のB細胞リンパ腫治療市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • タイプ別の世界のB細胞リンパ腫治療市場の成長機会
    • 最終用途別の世界のB細胞リンパ腫治療市場の成長機会
    • 流通チャネル別の世界のB細胞リンパ腫治療市場の成長機会
    • 地域別の世界のB細胞リンパ腫治療市場の成長機会
  • 世界のB細胞リンパ腫治療市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のB細胞リンパ腫治療市場の能力拡大
    • 世界のB細胞リンパ腫治療市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Pfizer
  • Celgene Corporation
  • Eli Lilly
  • Novartis
  • Genentech
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Eisai
  • Amgen
  • Merck
目次

B-Cell Lymphoma Treatment Trends and Forecast

The future of the global B-cell lymphoma treatment market looks promising with opportunities in the hospital, specialty clinic, and home healthcare markets. The global B-cell lymphoma treatment market is expected to reach an estimated $10.28 billion by 2030 with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are growing incidence of B-cell lymphomas and on-going advancements in the treatment options.

A more than 150-page report is developed to help in your business decisions.

B-Cell Lymphoma Treatment by Segment

The study includes a forecast for the global B-cell lymphoma treatment by type, end use, distribution channel, and region.

B-Cell Lymphoma Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Diffuse Large B-Cell Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Hairy Cell Leukemia
  • Primary Central Nervous System Lymphoma
  • Primary Intraocular Lymphoma
  • Others

B-Cell Lymphoma Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

B-Cell Lymphoma Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

B-Cell Lymphoma Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of B-Cell Lymphoma Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies B-cell lymphoma treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the B-cell lymphoma treatment companies profiled in this report include-

  • Pfizer
  • Celgene Corporation
  • Eli Lilly
  • Novartis
  • Genentech
  • Astrazeneca
  • F. Hoffmann-La Roche
  • Eisai
  • Amgen
  • Merck

B-Cell Lymphoma Treatment Market Insights

Lucintel forecasts that diffuse large B-cell lymphoma will remain the largest segment over the forecast period due to increase number of cases and growing prevalence of B-cell lymphomas.

Within this market, hospital will remain the largest segment as it provides necessary equipment and expertise to perform a wide range of B-cell lymphoma treatments.

North America will remain the largest segment over the forecast period due to presence of well-developed healthcare system with access to the latest B-cell lymphoma treatments in the region.

Features of the Global B-Cell Lymphoma Treatment Market

Market Size Estimates: B-cell lymphoma treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: B-cell lymphoma treatment market size by type, end use, distribution channel, and region in terms of value ($B).

Regional Analysis: B-cell lymphoma treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, end uses, distribution channels, and regions for the B-cell lymphoma treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the B-cell lymphoma treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the B-cell lymphoma treatment market size?

Answer: The global B-cell lymphoma treatment market is expected to reach an estimated $10.28 billion by 2030.

Q.2 What is the growth forecast for B-cell lymphoma treatment market?

Answer: The global B-cell lymphoma treatment market is expected to grow with a CAGR of 7.8% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the B-cell lymphoma treatment market?

Answer: The major drivers for this market are growing incidence of B-cell lymphomas and on-going advancements in the treatment options.

Q4. What are the major segments for B-cell lymphoma treatment market?

Answer: The future of the global B-cell lymphoma treatment market looks promising with opportunities in the hospital, specialty clinic, and home healthcare markets.

Q5. Who are the key B-cell lymphoma treatment market companies?

Answer: Some of the key B-cell lymphoma treatment companies are as follows:

  • Pfizer
  • Celgene Corporation
  • Eli Lilly
  • Novartis
  • Genentech
  • Astrazeneca
  • F. Hoffmann-La Roche
  • Eisai
  • Amgen
  • Merck

Q6. Which B-cell lymphoma treatment market segment will be the largest in future?

Answer: Lucintel forecasts that diffuse large B-cell lymphoma is expected to witness highest growth over the forecast period due to fast-growing lymphoma that can affect people of all ages, but it is most common in older adults.Lucintel forecasts that diffuse large B-cell lymphoma will remain the largest segment over the forecast period due to increase number of cases and growing prevalence of B-cell lymphomas.

Q7. In B-cell lymphoma treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to presence of well-developed healthcare system with access to the latest B-cell lymphoma treatments in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the B-cell lymphoma treatment market by type (diffuse large B-cell lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, primary central nervous system lymphoma, primary intraocular lymphoma, and others), end use (hospitals, specialty clinics, home healthcare, and others), distribution channel (direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global B-Cell Lymphoma Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global B-Cell Lymphoma Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global B-Cell Lymphoma Treatment Market by Type
    • 3.3.1: Diffuse Large B-Cell Lymphoma
    • 3.3.2: Lymphoplasmacytic Lymphoma
    • 3.3.3: Hairy Cell Leukemia
    • 3.3.4: Primary Central Nervous System Lymphoma
    • 3.3.5: Primary Intraocular Lymphoma
    • 3.3.6: Others
  • 3.4: Global B-Cell Lymphoma Treatment Market by End Use
    • 3.4.1: Hospitals
    • 3.4.2: Specialty Clinics
    • 3.4.3: Home Healthcare
    • 3.4.4: Others
  • 3.5: Global B-Cell Lymphoma Treatment Market by Distribution Channel
    • 3.5.1: Direct Tender
    • 3.5.2: Hospital Pharmacy
    • 3.5.3: Retail Pharmacy
    • 3.5.4: Online Pharmacy
    • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global B-Cell Lymphoma Treatment Market by Region
  • 4.2: North American B-Cell Lymphoma Treatment Market
    • 4.2.2: North American B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
  • 4.3: European B-Cell Lymphoma Treatment Market
    • 4.3.1: European B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
    • 4.3.2: European B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
  • 4.4: APAC B-Cell Lymphoma Treatment Market
    • 4.4.1: APAC B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
    • 4.4.2: APAC B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
  • 4.5: ROW B-Cell Lymphoma Treatment Market
    • 4.5.1: ROW B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
    • 4.5.2: ROW B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by End Use
    • 6.1.3: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Region
  • 6.2: Emerging Trends in the Global B-Cell Lymphoma Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global B-Cell Lymphoma Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global B-Cell Lymphoma Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Pfizer
  • 7.2: Celgene Corporation
  • 7.3: Eli Lilly
  • 7.4: Novartis
  • 7.5: Genentech
  • 7.6: AstraZeneca
  • 7.7: F. Hoffmann-La Roche
  • 7.8: Eisai
  • 7.9: Amgen
  • 7.10: Merck